Cart
sales@molnova.com
Ac-YVAD-AOM
CAS No. 154674-81-4
Ac-YVAD-AOM( —— )
Catalog No. M37204 CAS No. 154674-81-4
Ac-YVAD-AOM is a selective and potent caspase-1 inhibitor showing antitumor activity and potential analgesic activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 170 | In Stock |
|
| 10MG | 297 | In Stock |
|
| 25MG | 656 | In Stock |
|
| 50MG | 892 | In Stock |
|
| 100MG | 1190 | In Stock |
|
| 200MG | 1600 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAc-YVAD-AOM
-
NoteResearch use only, not for human use.
-
Brief DescriptionAc-YVAD-AOM is a selective and potent caspase-1 inhibitor showing antitumor activity and potential analgesic activity.
-
DescriptionAc-YVAD-AOM is the inhibitor of caspase-1 that shows antitumor activity.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetCaspase
-
RecptorCaspase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number154674-81-4
-
Formula Weight654.71
-
Molecular FormulaC33H42N4O10
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES[C@H](CC1=CC=C(O)C=C1)(C(N[C@H](C(N[C@H](C(N[C@H](C(COC(=O)C2=C(C)C=CC=C2C)=O)CC(O)=O)=O)C)=O)C(C)C)=O)NC(C)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. S Schlosser, et al. Inhibition of caspase-1 induces cell death in pancreatic carcinoma cells and potentially modulates expression levels of bcl-2 family proteins. FEBS Lett. 2001 Feb 23;491(1-2):104-8.?
molnova catalog
related products
-
Z-VAD(OH)-FMK
Z-VAD-FMK (Caspase Inhibitor VI) is an irreversible pan-caspase inhibitor.
-
Ac-YVAD-CHO
Ac-YVAD-CHO (L 709049) is a selective and potent tetrapeptide interleukin 1β-converting enzyme (ICE) and caspase-1 (ICE)-like protease inhibitor with anti-inflammatory activity.
-
Raptinal
Raptinal activates caspase-3 directly and initiates intrinsic caspase-dependent apoptosis pathway in multiple cell lines.
